durvalumab,naptumomab
astrazeneca,Active Biotech,Stayble Therapeutics,NeoTX
['durva', '$stab']
active biotech $acti safety and preliminary activity of naptumomab in combination with durvalumab presented at aacr 2023 stayble therapeutics $stabl appointed jarkko kalliom ki to chief medical officer 
Business Intelligence on European listed biotech companies
Subscription Plan now available for retail customers